FDA Approves Opdivo Label Expansion for Hodgkin Lymphoma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BMY?
Source: seekingalpha
- Indication Expansion: The FDA has approved Bristol Myers Squibb's Opdivo for treating newly diagnosed Stage III or IV classical Hodgkin lymphoma patients as part of a first-line combination regimen, which is expected to significantly enhance the drug's market share in blood cancer treatment.
- Supplemental Biologics Application: This approval is based on the supplemental Biologics License Application submitted by Bristol Myers Squibb, covering patients aged 12 and older, further solidifying Opdivo's position in oncology, particularly its potential use in younger patients.
- Traditional Approval: The FDA has concurrently granted traditional approval for Opdivo to treat adults with relapsed or refractory classical Hodgkin lymphoma as a late-line option under specific circumstances, providing more treatment options for patients and enhancing the drug's clinical applicability.
- Future Outlook: The FDA has set April 8, 2026, as the target action date for this supplemental application and granted priority review, indicating a positive outlook from regulators on Opdivo's potential in blood cancer treatment, which may drive long-term growth for Bristol Myers Squibb.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.110
Low
37.00
Averages
55.86
High
68.00
Current: 58.110
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Opdivo Label Expansion for Hodgkin Lymphoma
- Indication Expansion: The FDA has approved Bristol Myers Squibb's Opdivo for treating newly diagnosed Stage III or IV classical Hodgkin lymphoma patients as part of a first-line combination regimen, which is expected to significantly enhance the drug's market share in blood cancer treatment.
- Supplemental Biologics Application: This approval is based on the supplemental Biologics License Application submitted by Bristol Myers Squibb, covering patients aged 12 and older, further solidifying Opdivo's position in oncology, particularly its potential use in younger patients.
- Traditional Approval: The FDA has concurrently granted traditional approval for Opdivo to treat adults with relapsed or refractory classical Hodgkin lymphoma as a late-line option under specific circumstances, providing more treatment options for patients and enhancing the drug's clinical applicability.
- Future Outlook: The FDA has set April 8, 2026, as the target action date for this supplemental application and granted priority review, indicating a positive outlook from regulators on Opdivo's potential in blood cancer treatment, which may drive long-term growth for Bristol Myers Squibb.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Bristol Myers Squibb to Announce Q1 2026 Results
- Earnings Announcement Schedule: Bristol Myers Squibb will announce its Q1 2026 financial results on April 30, 2026, with executives reviewing the results during a conference call at 8:00 a.m. ET, ensuring transparency and information sharing with stakeholders.
- Investor Participation: Investors and the public are invited to listen to the live audio webcast of the call, reflecting the company's commitment to investor communication and enhancing engagement with its stakeholders.
- Preparation of Meeting Materials: Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call, ensuring participants have access to necessary information in advance, thereby improving the effectiveness and engagement of the meeting.
- Webcast Replay Service: A replay of the webcast will be available approximately three hours after the conference call concludes, allowing investors who could not participate live to review the meeting content, further enhancing accessibility and transparency of information.
See More
Evotec and BMS Initiate Phase 1 Clinical Trial for Kidney Cancer Treatment
- Clinical Trial Launch: The initiation of Phase 1 clinical trial for BMS-986506 in advanced clear cell renal cell carcinoma marks a significant advancement in the strategic collaboration between Evotec and BMS, potentially establishing a new treatment paradigm for kidney cancer.
- Milestone Payment: Evotec will receive a $10 million milestone payment as a result of this clinical progression, which not only strengthens the company's financial position but also reflects its technological prowess in the protein degradation field.
- Technology Validation: The trial validates Evotec's capabilities in high-performance multi-omics screening and AI-supported data analytics, showcasing its potential in developing novel molecular glue drugs that could reshape cancer treatment standards.
- Deepening Strategic Collaboration: Since the partnership with BMS began in 2018, Evotec has been advancing molecular glue drug development through its PanOmics and PanHunter platforms, aiming to address significant unmet medical needs and further solidify its leadership in the biopharmaceutical sector.
See More
Bristol Myers Squibb Stock Shows Strong Performance Amid Market Turmoil
- Strong Stock Performance: Bristol Myers Squibb (BMY) has achieved a double-digit gain year-to-date, standing out in a declining market, which highlights its defensive appeal for investors seeking stable returns during turbulent times.
- Growth Portfolio Transition: Despite facing a patent cliff, the company's growth portfolio accounted for 55% of total revenue in 2025, up from 47% the previous year, indicating a successful transformation and enhanced future revenue potential.
- Robust R&D Pipeline: The company expects to report results from 28 pivotal clinical studies by the end of 2028, with half being new therapies and the other half new indications for approved drugs, demonstrating its ongoing commitment to innovative drug development.
- Stable Dividend Yield: Bristol Myers Squibb boasts a forward dividend yield exceeding 4.2% and has paid dividends for 94 consecutive years, increasing them for 17 straight years, which enhances its attractiveness as a defensive investment amid rising market uncertainties.
See More
Bristol Myers Squibb: A Stable Defensive Stock Amid Market Turbulence
- Strong Stock Performance: Bristol Myers Squibb (BMY) has achieved a double-digit year-to-date gain amidst market volatility, with a current price of $59.71 and a market cap of $122 billion, highlighting its appeal as a defensive stock.
- Revenue Structure Transformation: By 2025, the company's growth portfolio is expected to account for 55% of total revenue, up from 47% the previous year, indicating a proactive strategy to address patent cliff challenges.
- Robust R&D Pipeline: Bristol Myers Squibb plans to report pivotal clinical study results for 28 programs by the end of 2028, with half being new therapies and the other half new indications for approved drugs, showcasing its ongoing innovation potential.
- Stable Dividend Yield: The company has paid dividends for 94 consecutive years and increased its dividend for 17 straight years, with a current yield exceeding 4.2%, providing reliable returns for income investors.
See More
FDA Approves Opdivo Label Expansion for Hodgkin Lymphoma
- Indication Expansion: The FDA has approved Bristol Myers Squibb's Opdivo for treating newly diagnosed Stage III or IV classical Hodgkin lymphoma patients as part of a first-line combination regimen, which is expected to significantly enhance the drug's market share in blood cancer treatment.
- Supplemental Biologics Application: This approval is based on the supplemental Biologics License Application submitted by Bristol Myers Squibb, covering patients aged 12 and older, further solidifying Opdivo's position in oncology, particularly its potential use in younger patients.
- Traditional Approval: The FDA has concurrently granted traditional approval for Opdivo to treat adults with relapsed or refractory classical Hodgkin lymphoma as a late-line option under specific circumstances, providing more treatment options for patients and enhancing the drug's clinical applicability.
- Future Outlook: The FDA has set April 8, 2026, as the target action date for this supplemental application and granted priority review, indicating a positive outlook from regulators on Opdivo's potential in blood cancer treatment, which may drive long-term growth for Bristol Myers Squibb.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Bristol Myers Squibb to Announce Q1 2026 Results
- Earnings Announcement Schedule: Bristol Myers Squibb will announce its Q1 2026 financial results on April 30, 2026, with executives reviewing the results during a conference call at 8:00 a.m. ET, ensuring transparency and information sharing with stakeholders.
- Investor Participation: Investors and the public are invited to listen to the live audio webcast of the call, reflecting the company's commitment to investor communication and enhancing engagement with its stakeholders.
- Preparation of Meeting Materials: Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call, ensuring participants have access to necessary information in advance, thereby improving the effectiveness and engagement of the meeting.
- Webcast Replay Service: A replay of the webcast will be available approximately three hours after the conference call concludes, allowing investors who could not participate live to review the meeting content, further enhancing accessibility and transparency of information.
See More
Evotec and BMS Initiate Phase 1 Clinical Trial for Kidney Cancer Treatment
- Clinical Trial Launch: The initiation of Phase 1 clinical trial for BMS-986506 in advanced clear cell renal cell carcinoma marks a significant advancement in the strategic collaboration between Evotec and BMS, potentially establishing a new treatment paradigm for kidney cancer.
- Milestone Payment: Evotec will receive a $10 million milestone payment as a result of this clinical progression, which not only strengthens the company's financial position but also reflects its technological prowess in the protein degradation field.
- Technology Validation: The trial validates Evotec's capabilities in high-performance multi-omics screening and AI-supported data analytics, showcasing its potential in developing novel molecular glue drugs that could reshape cancer treatment standards.
- Deepening Strategic Collaboration: Since the partnership with BMS began in 2018, Evotec has been advancing molecular glue drug development through its PanOmics and PanHunter platforms, aiming to address significant unmet medical needs and further solidify its leadership in the biopharmaceutical sector.
See More
Bristol Myers Squibb Stock Shows Strong Performance Amid Market Turmoil
- Strong Stock Performance: Bristol Myers Squibb (BMY) has achieved a double-digit gain year-to-date, standing out in a declining market, which highlights its defensive appeal for investors seeking stable returns during turbulent times.
- Growth Portfolio Transition: Despite facing a patent cliff, the company's growth portfolio accounted for 55% of total revenue in 2025, up from 47% the previous year, indicating a successful transformation and enhanced future revenue potential.
- Robust R&D Pipeline: The company expects to report results from 28 pivotal clinical studies by the end of 2028, with half being new therapies and the other half new indications for approved drugs, demonstrating its ongoing commitment to innovative drug development.
- Stable Dividend Yield: Bristol Myers Squibb boasts a forward dividend yield exceeding 4.2% and has paid dividends for 94 consecutive years, increasing them for 17 straight years, which enhances its attractiveness as a defensive investment amid rising market uncertainties.
See More
Bristol Myers Squibb: A Stable Defensive Stock Amid Market Turbulence
- Strong Stock Performance: Bristol Myers Squibb (BMY) has achieved a double-digit year-to-date gain amidst market volatility, with a current price of $59.71 and a market cap of $122 billion, highlighting its appeal as a defensive stock.
- Revenue Structure Transformation: By 2025, the company's growth portfolio is expected to account for 55% of total revenue, up from 47% the previous year, indicating a proactive strategy to address patent cliff challenges.
- Robust R&D Pipeline: Bristol Myers Squibb plans to report pivotal clinical study results for 28 programs by the end of 2028, with half being new therapies and the other half new indications for approved drugs, showcasing its ongoing innovation potential.
- Stable Dividend Yield: The company has paid dividends for 94 consecutive years and increased its dividend for 17 straight years, with a current yield exceeding 4.2%, providing reliable returns for income investors.
See More
